BioXcel Therapeutics (NASDAQ:BTAI) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of BioXcel Therapeutics (NASDAQ:BTAI) in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the stock. UBS Group reissued a neutral rating and set a $4.00 price objective (down previously from $9.00) on shares of BioXcel Therapeutics in a research report on Wednesday, February 21st. Canaccord Genuity Group dropped their price target on BioXcel Therapeutics from $18.00 to $7.00 and set a buy rating on the stock in a research note on Thursday, March 14th. Finally, Bank of America reduced their price objective on BioXcel Therapeutics from $8.00 to $7.00 and set a buy rating for the company in a research note on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Hold and a consensus price target of $16.71.

BioXcel Therapeutics Stock Down 9.3 %

BTAI traded down $0.22 during trading on Friday, hitting $2.09. The company’s stock had a trading volume of 696,007 shares, compared to its average volume of 469,256. The firm has a market capitalization of $77.39 million, a P/E ratio of -0.40 and a beta of 0.43. BioXcel Therapeutics has a twelve month low of $1.91 and a twelve month high of $28.94. The stock’s fifty day moving average price is $2.71 and its 200-day moving average price is $3.15.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.19). The company had revenue of $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. BioXcel Therapeutics had a negative net margin of 8,715.72% and a negative return on equity of 890.63%. During the same quarter in the prior year, the firm earned ($1.84) EPS. Equities research analysts expect that BioXcel Therapeutics will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On BioXcel Therapeutics

A number of hedge funds have recently added to or reduced their stakes in BTAI. Vanguard Group Inc. lifted its holdings in shares of BioXcel Therapeutics by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock valued at $3,100,000 after purchasing an additional 9,912 shares in the last quarter. Virtu Financial LLC purchased a new stake in BioXcel Therapeutics in the 4th quarter valued at $176,000. Pennant Investors LP bought a new position in BioXcel Therapeutics during the 4th quarter valued at $248,000. Tower Research Capital LLC TRC boosted its holdings in BioXcel Therapeutics by 239.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,832 shares of the company’s stock worth $41,000 after acquiring an additional 9,754 shares during the last quarter. Finally, Apollon Wealth Management LLC bought a new stake in shares of BioXcel Therapeutics in the 4th quarter worth $31,000. Institutional investors and hedge funds own 30.68% of the company’s stock.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.